Related Experiment Video
Updated: Aug 13, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
[Pharmacodynamic tests of wulong kangai on transplantable tumors in mice]
Ya-qian Liu1, Chun-hai Li, Geng-lu Yang
1Centra Animal Experimental Laboratory, General Hospital of PLA, Beijing 100853, China. liuyaqian@yahoo.com.cn
Objective:
To observe the pharmacodynamic and side effects of Wulong Kangai, a new drug of Chinese traditional herbal medicine, on 4 strains of mice transplantable tumors.
Method:
Mice transplantable tumors S180, H22, P388 and Lewis were used in the pharmacodynamic test on the granules of Wulong Kangai. The test on each tumor strain was repeated three times. In each test, 50 mice were used and divided into 5 groups. They were negative control group treated by physiological saline, cyclophosphamide control group and 3 test groups treated respectively with Wulong Kangai at deferent dosages of 10, 25, 40 g x kg(-1) x d(-1) in the treatment of Lewis and P388 and 15, 30, 50 g x kg(-1) x d(-1) in the treatment of S180 and H22.
Result:
The tumor weight were inhibited at the rates of 90.1%, 30.8%, 49.8% and 52. 3% in the mice with tumors of Lewis, P388, S180, and H22 by high dosage of Wulong Kangai as compared with negative control group. The inhibitory rates in cyclophosphamide groups were 90.6%, 77.2%, 79.6% and 60.3% respectively. The mice body weights grew slower in high dose groups treated by Wulong Kangai granule.
Conclusion:
Wulong Kangai was effective in treating mice transplantable tumors of Lewis, P388, S180 and H22 with a dose-dependent manner. The Lewis was the most sensitive strain to the drug among the 4 kinds of tested tumors. Side effects appeared during 9-11 days of uninterrupted treatment with high dose Wulong Kangai.
Insights
Wulong Kangai demonstrated significant efficacy against four mouse transplantable tumors in a dose-dependent manner. Lewis tumors showed the highest sensitivity, though high doses caused slower body weight gain and side effects.
Area of Science:
- Pharmacology
- Oncology
- Traditional Chinese Medicine
Context:
- Cancer research often utilizes animal models to evaluate potential therapeutic agents.
- Traditional Chinese Medicine (TCM) offers a rich source of compounds for drug discovery.
- Understanding the efficacy and safety of novel TCM-based drugs is crucial for clinical translation.
Purpose:
- To evaluate the pharmacodynamic effects of Wulong Kangai, a novel TCM drug, on four distinct strains of mouse transplantable tumors.
- To assess the dose-dependent efficacy and identify potential side effects of Wulong Kangai treatment.
- To compare the efficacy of Wulong Kangai against standard chemotherapy (cyclophosphamide) in preclinical models.
Summary:
- Wulong Kangai treatment resulted in significant tumor weight inhibition across Lewis, P388, S180, and H22 mouse tumor models.
- High-dose Wulong Kangai achieved inhibition rates of 90.1% (Lewis), 30.8% (P388), 49.8% (S180), and 52.3% (H22).
- Lewis tumors exhibited the highest sensitivity to Wulong Kangai, with observed side effects including slower body weight gain after prolonged high-dose treatment.
Impact:
- This study provides preclinical evidence for the anti-tumor activity of Wulong Kangai, particularly against Lewis tumors.
- Findings support further investigation into Wulong Kangai as a potential therapeutic agent for specific transplantable tumors.
- The observed dose-dependent effects and side effects profile inform future research and development strategies for this TCM-derived drug.
